{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:57:45Z","timestamp":1793923065442,"version":"4.8.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Chemotherapy (CTX) is an important part of the treatment strategy of stage II\u2013IV ovarian cancer. CTX modifications, such as delays, dose reductions or premature terminations might have a negative impact on overall survival (OS) and progression free survival (PFS). The goal of this study was to determine the incidence and predictors of CTX modifications and their influence on survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An observational retrospective cohort analysis of 192 ovarian cancer patients who were treated at the Department of Obstetrics and Gynaecology, Technical University Munich, Germany, according to international guidelines was performed including from 2009 to 2013. A potential association between patient and disease characteristics and CTX modifications was tested with multivariate logistic regression. OS and PFS were estimated by Kaplan\u2013Meier analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>44.8% (86\/192) received a modification of CTX. 34 (17.7%) women discontinued CTX prematurely, 17 (8.9%) underwent a dose reduction, 16 (8.3%) experienced a CTX delay and 10 (5.2%) had both a delay and a dose modification. In nine (4.7%) patients, the dose needed to be divided. Leukopenia (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and anaemia (<jats:italic>p<\/jats:italic>\u2009=\u20090.003) were significantly more common in patients with CTX modifications. Significant predictors for CTX modifications were a history of thrombosis or embolism (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and residual tumour postoperatively (<jats:italic>p<\/jats:italic>\u2009=\u20090.003).<\/jats:p>\n                <jats:p>Patients with CTX modifications showed a significantly lower OS as well as PFS (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), even after adjustment for prognostic factors such as age, body-mass-index, residual tumour, histology, FIGO stage and grading (<jats:italic>p<\/jats:italic>\u2009=\u20090.005 for OS and <jats:italic>p<\/jats:italic>\u2009=\u20090.001 for PFS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>CTX modifications have a negative impact on survival. Significant predictors for such modifications are a history of thrombosis or embolism and the presence of residual postoperative tumour. Further studies are needed to avoid CTX modifications and to improve survival of ovarian cancer patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-022-06813-9","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T06:04:38Z","timestamp":1667455478000},"page":"1891-1899","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Incidence and predictors for chemotherapy modifications and their impact on the outcome of ovarian cancer patients"],"prefix":"10.1007","volume":"307","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3363-0079","authenticated-orcid":false,"given":"Sandra","family":"Hatsy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Brambs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Kiechle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"6813_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA (2017) Epidemiology of ovarian cancer a review. Cancer Biol Med 14:9\u201332","journal-title":"Cancer Biol Med"},{"key":"6813_CR2","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner. Ovarialtumoren, Langversion 5.0, 2021, AWMF-Registernummer: 032\/035OL, https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/ovarialkarzinom\/"},{"issue":"3","key":"6813_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ygyno.2019.02.015","volume":"153","author":"T Heilmann","year":"2019","unstructured":"Heilmann T, Pfisterer J, Hempel AM, Sa\u00df S, Hedderich J, Pujade-Lauraine E et al (2019) Early treatment modifications improve chemotherapy adherence in ovarian cancer patients \u226570 years. Gynecol Oncol 153(3):616\u2013624. https:\/\/doi.org\/10.1016\/j.ygyno.2019.02.015","journal-title":"Gynecol Oncol"},{"issue":"1","key":"6813_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/COC.0000000000000469","volume":"42","author":"L Salman","year":"2019","unstructured":"Salman L, Ben-Haroush A, Raban O, Yeoshoua E, Sabah G, Jakobson-Setton A et al (2019) Neoadjuvant chemotherapy treatment modifications in ovarian carcinoma: the impact on surgical outcome and progression-free survival. Ame J Clin Oncol 42(1):17\u201320. https:\/\/doi.org\/10.1097\/COC.0000000000000469","journal-title":"Ame J Clin Oncol"},{"issue":"5","key":"6813_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","volume":"18","author":"N Denduluri","year":"2018","unstructured":"Denduluri N, Lyman GH, Wang Y, Morrow PK, Barron R, Patt D et al (2018) Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer. Clin Breast Cancer 18(5):380\u2013386. https:\/\/doi.org\/10.1016\/j.clbc.2018.02.003","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"6813_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ygyno.2015.03.052","volume":"137","author":"N Joseph","year":"2015","unstructured":"Joseph N, Clark RM, Dizon DS, Lee MS, Goodman A, Boruta D et al (2015) Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer. Gynecol Oncol 137(3):401\u2013405","journal-title":"Gynecol Oncol"},{"key":"6813_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1104-5","author":"S Liutkauskiene","year":"2015","unstructured":"Liutkauskiene S, Janciauskiene R, Jureniene K, Grizas S, Malonyte R, Juozaityte E (2015) Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-015-1104-5","journal-title":"BMC Cancer"},{"issue":"1","key":"6813_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","volume":"129","author":"RK Hanna","year":"2013","unstructured":"Hanna RK, Poniewierski MS, Laskey RA, Lopez MA, Shafer A, van Le L et al (2013) Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol 129(1):74\u201380. https:\/\/doi.org\/10.1016\/j.ygyno.2012.12.017","journal-title":"Gynecol Oncol"},{"issue":"1","key":"6813_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169272","volume":"12","author":"V Seebacher","year":"2017","unstructured":"Seebacher V, Reinthaller A, Koelbl H, Concin N, Nehoda R, Polterauer S (2017) The impact of the duration of adjuvant chemotherapy on survival in patients with epithelial ovarian cancer - a retrospective study. PLoS ONE 12(1):e0169272. https:\/\/doi.org\/10.1371\/journal.pone.0169272","journal-title":"PLoS ONE"},{"issue":"2","key":"6813_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ygyno.2011.10.003","volume":"124","author":"CI Nagel","year":"2012","unstructured":"Nagel CI, Backes FJ, Hade EM, Cohn DE, Eisenhauer EL, O\u2019Malley DM et al (2012) Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer. Gynecol Oncol 124(2):221\u2013224. https:\/\/doi.org\/10.1016\/j.ygyno.2011.10.003","journal-title":"Gynecol Oncol"},{"issue":"2","key":"6813_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0959-8049(93)90169-G","volume":"29","author":"L Repetto","year":"1993","unstructured":"Repetto L, Pace M, Mammoliti S, Bruzzone M, Chiara S, Oliva C et al (1993) The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer 29(2):181\u2013184","journal-title":"Eur J Cancer"},{"key":"6813_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.12.058","author":"A Olawaiye","year":"2012","unstructured":"Olawaiye A, Java J, Krivak T, Bookman M, Herzog T (2012) Does maintaining adjuvant chemotherapy dose intensity have an impact on the outcome of treatment in ovarian cancer patients? A Gynecologic Oncology Group study. Gynecol Oncol. https:\/\/doi.org\/10.1016\/j.ygyno.2011.12.058","journal-title":"Gynecol Oncol"},{"issue":"7","key":"6813_CR13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/sj.bjc.6604298","volume":"98","author":"JD Wright","year":"2008","unstructured":"Wright JD, Doan T, McBride R, Jacobson JS, Hershman Dl (2008) Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. British J Cancer 98(7):1197\u20131203. https:\/\/doi.org\/10.1038\/sj.bjc.6604298","journal-title":"British J Cancer"},{"issue":"1","key":"6813_CR14","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ejogrb.2013.06.004","volume":"170","author":"FA Saadeh","year":"2013","unstructured":"Saadeh FA, Norris L, O\u2019Toole S, Gleeson N (2013) Venous thromboembolism in ovarian cancer. Incidence, risk factors and impact on survival. Eur J Obstet Gynecol Reprod Biol 170(1):214\u2013218. https:\/\/doi.org\/10.1016\/j.ejogrb.2013.06.004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"10","key":"6813_CR15","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1007\/s00520-016-3258-3","volume":"24","author":"L Family","year":"2016","unstructured":"Family L, Xu L, Xu H, Cannavale K, Sattayapiwat O, Page JH et al (2016) The effect of chemotherapy-induced anemia on dose reduction and dose delay. Support Care Cancer 24(10):4263\u20134271. https:\/\/doi.org\/10.1007\/s00520-016-3258-3","journal-title":"Support Care Cancer"},{"issue":"1","key":"6813_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2354.2007.00797.x","volume":"17","author":"S Khan","year":"2008","unstructured":"Khan S, Dhadda A, Fyfe D, Sundar S (2008) Impact of neutropenia on delivering planned chemotherapy for solid tumours. Eur J Cancer Care 17(1):19\u201325. https:\/\/doi.org\/10.1111\/j.1365-2354.2007.00797.x","journal-title":"Eur J Cancer Care"},{"issue":"4","key":"6813_CR17","first-page":"CR156","volume":"15","author":"MH Eichbaum","year":"2009","unstructured":"Eichbaum MH, Weiss LM, Bruckner T, Schneeweiss A, Sinn HP, Gebauer G, Fersis N, Kussmaul J, Sohn C (2009) Prognostic impact of hemoglobin levels before and during carboplatin\/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. Med Sci Monit 15(4):CR156\u2013CR163 (PMID: 19333199)","journal-title":"Med Sci Monit"},{"issue":"3","key":"6813_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1471-0528.2008.02033.x","volume":"116","author":"CG Gerestein","year":"2009","unstructured":"Gerestein CG, Eijkemans MJ, de Jong D, van der Burg ME, Dykgraaf RH, Kooi GS, Baalbergen A, Burger CW, Ansink AC (2009) The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG 116(3):372\u2013380. https:\/\/doi.org\/10.1111\/j.1471-0528.2008.02033.x (PMID: 19187369)","journal-title":"BJOG"},{"issue":"5","key":"6813_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3109\/00016341003674913","volume":"89","author":"JJ Kim","year":"2010","unstructured":"Kim JJ, Park JY, Kim DY, Kim JH, Kim YM, Nam JH, Kim YT (2010) Is chemotherapy-induced neutropenia a prognostic factor in patients with ovarian cancer? Acta Obstet Gynecol Scand 89(5):623\u2013628. https:\/\/doi.org\/10.3109\/00016341003674913 (PMID: 20423275)","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"6813_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.ygyno.2014.03.013","volume":"133","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Java JJ, Gatcliffe TA, Bookman MA, Monk BJ (2014) Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group. Gynecol Oncol 133(3):439\u2013445. https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.013 (Epub 2014 Mar 20 PMID: 24657300)","journal-title":"Gynecol Oncol"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06813-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-022-06813-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-022-06813-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T09:12:01Z","timestamp":1682673121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-022-06813-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["6813"],"URL":"https:\/\/doi.org\/10.1007\/s00404-022-06813-9","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]},"assertion":[{"value":"12 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}